key: cord-0891575-kpoujitd
authors: Chuang, Tzu-Yi; Tsai, Ming-Han; Wu, Lit-Min; Ho, Sung-Jung; Yeh, Pu-Sheng; Liu, Yi-Lien; Fred Yang, Hung-Jen
title: Successful treatment of tocilizumab and ivermectin for a patient with ARDS due to COVID-19
date: 2020-10-03
journal: J Microbiol Immunol Infect
DOI: 10.1016/j.jmii.2020.09.007
sha: 672336ba25953b98be1b94ae3f7ab98e40e11e19
doc_id: 891575
cord_uid: kpoujitd

nan

Successful treatment of tocilizumab and ivermectin for a patient with ARDS due to Dear Editor:

Acute respiratory distress syndrome (ARDS) is one of the consequences of the cytokine release syndrome (CRS) triggered by coronavirus disease 2019 (COVID-19). 1 Tocilizumab (TCZ), a recombinant IL-6 inhibitor, is a potentially beneficial treatment for CRS caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 2 Ivermectin, an antiparasitic drug, acts as a potential inhibitor of the coronavirus. 3 The combination of TCZ and Ivermectin could be a potential treatment for COVID-19related ARDS.

A 68-y/o female was admitted to the hospital for COVID-19 after returning from Indonesia. The chest radiograph revealed bilateral subpleural infiltrates (Fig. 1A) . She was tested positive for SARS-CoV-2 and treated with hydroxychloroquine and azithromycin on hospital day 2. ARDS ( Fig. 1B) had developed on hospital day 4/ICU day 1, and intubation with lung protective-strategy and prone positioning was performed due to PaO 2 /FiO 2 ratio at 60 mmHg. Both hydroxychloroquine and azithromycin were discontinued due to QTc prolongation (709 ms) on hospital day 9/ICU day 6. We prescribed single dose of TCZ 240 mg for ARDS and checked for hyper-inflammatory response, including C-reactive protein (CRP) at 30.42 mg/dL (reference range: 0e0.5 mg/dL), lactate dehydrogenase (LDH) at 667 U/L (reference range: 125e220 U/L) and ferritin at 4125.77 ng/mL (reference range: 4.63e204 ng/mL) on hospital day 10/ICU day 7. Single dose of Ivermectin 12 mg was given on hospital day 12/ICU day 9 due to positive result of SARS-CoV-2 in sputum collected on hospital day 10/ICU day 7. After the Ivermectin treatment, the patient had 3 negative results on consecutive sputum examinations during hospital days 15e17/ICU days 12e14, and the PaO 2 / FiO 2 ratio increased gradually (from 91, 154 to 230 mmHg).

Her chest radiograph (Fig. 1C) showed improvement and hyper-inflammatory markers decreased gradually (CRP from 30.42 to 0.48 mg/dL, LDH from 667 to 342 IU, and ferritin from 4125.77 to 1000 ng/mL), which all confirmed our suspicion that the CRS induced by SARS-CoV-2 was the cause of ARDS. She had a smooth hospital discharge, but living with subpleural fibrosis (Fig. 1D) .

During the initial stage of infection, SARS-CoV-2 could trigger an adaptive immune response to fight against virus in our body and lead to a phase of CRS that cause ARDS. 1 Previous reports demonstrated that, in addition to CRP, LDH and ferritin, the IL-6 levels were elevated during SARS-CoV-2 infection. 2 CRP, LDH and ferritin could be used to predict the acuteness, severity and prognosis of COVID-19, and considered as a surrogate marker for IL-6 level. 2, 4 The hypothesized mechanism of Ivermectin was implicated in the blockade of viral protein transport in the nucleus of target cell, and significantly reducing the coronaviral RNA by more than 90% in 24 h. However, the report of clinical trials on Ivermectin for the treatment of COVID-19 are not yet available. 3 In this case, Ivermectin was the only one choice that could possibly treat SARS-CoV-2 in our patient under the circumstances of limited availability of Lopinavir/Ritonavir and Remdesivir, as well as the adverse effects in hydroxychloroquine and azithromycin. 5 The rationale of combination with Ivermectin and TCZ is to stop the coronavirus and to deal with the CRS-induced ARDS. To our knowledge, this is the first and unique reported case of successful treatment in the combination of TCZ and Ivermectin for ARDS induced by COVID-19. The combination therapy of IL-6 inhibitor and potential anticoronavirus agent deserves further investigation in SARS-CoV-2 related ARDS.

The COVID-19 cytokine storm; what we know so far. Front Immunol

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia

FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resist Updates

Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management

Treatment options for COVID-19: the reality and challenges